Jihye Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jihye Chung has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Sang-Won Lee
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
9 shared publications - Yong-Beom Park
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
9 shared publications - Jang Woo Ha
Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea
8 shared publications - Oh Chan Kwon
Division of Rheumatology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea
6 shared publications - Lucy Eunju Lee
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
5 shared publications - Taejun Yoon
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
3 shared publications
Latest Publications
- 30 October 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7515-7524
Association between baseline systemic immune-inflammation index and subsequent stroke in ANCA-associated vasculitis
- 30 October 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7515-7524
Association between baseline systemic immune-inflammation index and subsequent stroke in ANCA-associated vasculitis
- Open Access
Association Between Baseline Modified Novel Fibrosis Index and Subsequent Stroke in Patients with Microscopic Polyangiitis or Granulomatosis with Polyangiitis
Background and Objectives: This study investigated whether the baseline modified novel fibrosis index (mNFI) could predict subsequent stroke in patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA). Materials and Methods: This study included 268 patients with MPA or GPA who met the inclusion and exclusion criteria. Clinical data at diagnosis were collected. Baseline Birmingham Vasculitis Activity Score (BVAS), Five-Factor Score (FFS), and earliest Vasculitis Damage Index (eVDI) were recorded as MPA/GPA-specific indices, and erythrocyte sedimentation rate and C-reactive protein (CRP) levels were recorded as acute-phase reactants. mNFI was derived by deleting the constant ‘N’ from the NFI formula and was calculated as follows: serum bilirubin (mg/dL) × (alkaline phosphatase [IU/L])2 / platelet count (× 1000/mm3) / (serum albumin [g/dL])2. Results: Among the 268 patients with MPA (70.9%) or GPA (29.1%), the median age was 62.0 years, and 64.6% were women. During a median follow-up of 55.1 months, stroke occurred in 7.1% of patients. Baseline mNFI correlated significantly with age, FFS and CRP, but not with BVAS or eVDI. Multivariable Cox proportional hazards analysis showed that baseline mNFI (hazard ratio 1.079) was independently associated with subsequent stroke alongside CRP levels. Patients with baseline mNFI ≥1.08 had a higher risk of subsequent stroke and a lower cumulative stroke-free survival rate than those with baseline mNFI < 1.08. Conclusions: Baseline mNFI was associated with subsequent stroke in patients with MPA or GPA and may represent a readily available candidate marker for cerebrovascular risk assessment. Further validation is required before its routine clinical application.
Open AccessAssociation Between Baseline Modified Novel Fibrosis Index and Subsequent Stroke in Patients with Microscopic Polyangiitis or Granulomatosis with Polyangiitis
Background and Objectives: This study investigated whether the baseline modified novel fibrosis index (mNFI) could predict subsequent stroke in patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA). Materials and Methods: This study included 268 patients with MPA or GPA who met the inclusion and exclusion criteria. Clinical data at diagnosis were collected. Baseline Birmingham Vasculitis Activity Score (BVAS), Five-Factor Score (FFS), and earliest Vasculitis Damage Index (eVDI) were recorded as MPA/GPA-specific indices, and erythrocyte sedimentation rate and C-reactive protein (CRP) levels were recorded as acute-phase reactants. mNFI was derived by deleting the constant ‘N’ from the NFI formula and was calculated as follows: serum bilirubin (mg/dL) × (alkaline phosphatase [IU/L])2 / platelet count (× 1000/mm3) / (serum albumin [g/dL])2. Results: Among the 268 patients with MPA (70.9%) or GPA (29.1%), the median age was 62.0 years, and 64.6% were women. During a median follow-up of 55.1 months, stroke occurred in 7.1% of patients. Baseline mNFI correlated significantly with age, FFS and CRP, but not with BVAS or eVDI. Multivariable Cox proportional hazards analysis showed that baseline mNFI (hazard ratio 1.079) was independently associated with subsequent stroke alongside CRP levels. Patients with baseline mNFI ≥1.08 had a higher risk of subsequent stroke and a lower cumulative stroke-free survival rate than those with baseline mNFI < 1.08. Conclusions: Baseline mNFI was associated with subsequent stroke in patients with MPA or GPA and may represent a readily available candidate marker for cerebrovascular risk assessment. Further validation is required before its routine clinical application.
- 27 October 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7505-7514
Baseline neutrophil-to-HDL cholesterol ratio is associated with subsequent cerebrovascular accident in patients with microscopic polyangiitis or granulomatosis with polyangiitis
- 27 October 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (12) , 7505-7514
Baseline neutrophil-to-HDL cholesterol ratio is associated with subsequent cerebrovascular accident in patients with microscopic polyangiitis or granulomatosis with polyangiitis
- Open Access
Association Between the Earliest CALLY Index at Diagnosis and Progression to End-Stage Kidney Disease in Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Background and Objectives: This study aimed to determine whether the earliest C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index at diagnosis was associated with progression to end-stage kidney disease (ESKD) during follow-up in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and Methods: This study included 247 patients with MPA and GPA. The CALLY index was calculated as follows: serum albumin (g/L) × lymphocyte count (/mm3)/CRP (mg/L)/10,000. The earliest CALLY index was defined as the value calculated at diagnosis. ESKD, which occurred after diagnosis, was defined as a poor outcome in this study. Results: The median age of the 247 patients was 62.0 years and 64.4% were women. Among the 247 patients, 50 (20.2%) progressed to ESKD. The earliest CALLY index at diagnosis was significantly lower in patients with ESKD than those without ESKD (0.15 vs. 0.55). Receiver operating characteristic curve analysis showed that the earliest CALLY index had modest discriminatory performance for progression to ESKD, with an area under the curve of 0.663 and a cut-off value of 0.26. Patients with an earliest CALLY index ≤ 0.26 at diagnosis exhibited a significantly higher risk for progression to ESKD (relative risk 3.174) and a significantly reduced cumulative ESKD-free survival rate compared to those with an earliest CALLY index > 0.26 at diagnosis. Conclusions: This study has exploratory implications, as it is the first to report that the earliest CALLY index was associated with ESKD occurrence during follow-up in patients with MPA and GPA, despite its limited value as an independent predictor of ESKD.
Open AccessAssociation Between the Earliest CALLY Index at Diagnosis and Progression to End-Stage Kidney Disease in Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Background and Objectives: This study aimed to determine whether the earliest C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index at diagnosis was associated with progression to end-stage kidney disease (ESKD) during follow-up in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and Methods: This study included 247 patients with MPA and GPA. The CALLY index was calculated as follows: serum albumin (g/L) × lymphocyte count (/mm3)/CRP (mg/L)/10,000. The earliest CALLY index was defined as the value calculated at diagnosis. ESKD, which occurred after diagnosis, was defined as a poor outcome in this study. Results: The median age of the 247 patients was 62.0 years and 64.4% were women. Among the 247 patients, 50 (20.2%) progressed to ESKD. The earliest CALLY index at diagnosis was significantly lower in patients with ESKD than those without ESKD (0.15 vs. 0.55). Receiver operating characteristic curve analysis showed that the earliest CALLY index had modest discriminatory performance for progression to ESKD, with an area under the curve of 0.663 and a cut-off value of 0.26. Patients with an earliest CALLY index ≤ 0.26 at diagnosis exhibited a significantly higher risk for progression to ESKD (relative risk 3.174) and a significantly reduced cumulative ESKD-free survival rate compared to those with an earliest CALLY index > 0.26 at diagnosis. Conclusions: This study has exploratory implications, as it is the first to report that the earliest CALLY index was associated with ESKD occurrence during follow-up in patients with MPA and GPA, despite its limited value as an independent predictor of ESKD.
- Open Access
- 15 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (8) , 2720
Clinical Utility of Serum sCD200/sCD200R Ratios in Predicting Current Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Objectives: This study investigated whether serum soluble CD200 (sCD200) and soluble receptor for CD200 (sCD200R) concentrations and serum sCD200/sCD200R ratios at diagnosis could predict cross-sectional activity in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods: We included 70 patients with AAV in this pilot study, retrospectively reviewed their medical records, and collected clinical data at the time of AAV diagnosis. We also measured sCD200 and sCD200R in stored blood samples collected at diagnosis. In medical records, AAV activity at diagnosis had been assessed according to the Birmingham Vasculitis Activity Score (BVAS). The prediction potential of serum sCD200 and sCD200R concentrations and serum sCD200/sCD200R ratios for BVAS was evaluated using Pearson correlation analysis. Results: Among the 70 patients, the median age was 63.5 years, with 29 males and 41 females. Among the three CD200-related variables at diagnosis, serum sCD200/sCD200R ratios at diagnosis were significantly correlated with cross-sectional BVAS; however, serum sCD200 and sCD200R concentrations were not correlated with it. These results may indicate that serum sCD200/sCD200R ratios may better help predict cross-sectional AAV activity by increasing the range of opposing changes in the two variables. On the other hand, both serum sCD200 concentrations and serum sCD200/sCD200R ratios showed significant correlations with cross-sectional myeloperoxidase-ANCA titre, five-factor score, and serum creatinine levels at diagnosis. Conclusions: In this study, we demonstrated that serum sCD200/sCD200R ratios at diagnosis can be a useful and convenient biomarker to predict cross-sectional AAV activity calculated according to BVAS.
- 15 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (8) , 2720
Open AccessClinical Utility of Serum sCD200/sCD200R Ratios in Predicting Current Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Objectives: This study investigated whether serum soluble CD200 (sCD200) and soluble receptor for CD200 (sCD200R) concentrations and serum sCD200/sCD200R ratios at diagnosis could predict cross-sectional activity in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods: We included 70 patients with AAV in this pilot study, retrospectively reviewed their medical records, and collected clinical data at the time of AAV diagnosis. We also measured sCD200 and sCD200R in stored blood samples collected at diagnosis. In medical records, AAV activity at diagnosis had been assessed according to the Birmingham Vasculitis Activity Score (BVAS). The prediction potential of serum sCD200 and sCD200R concentrations and serum sCD200/sCD200R ratios for BVAS was evaluated using Pearson correlation analysis. Results: Among the 70 patients, the median age was 63.5 years, with 29 males and 41 females. Among the three CD200-related variables at diagnosis, serum sCD200/sCD200R ratios at diagnosis were significantly correlated with cross-sectional BVAS; however, serum sCD200 and sCD200R concentrations were not correlated with it. These results may indicate that serum sCD200/sCD200R ratios may better help predict cross-sectional AAV activity by increasing the range of opposing changes in the two variables. On the other hand, both serum sCD200 concentrations and serum sCD200/sCD200R ratios showed significant correlations with cross-sectional myeloperoxidase-ANCA titre, five-factor score, and serum creatinine levels at diagnosis. Conclusions: In this study, we demonstrated that serum sCD200/sCD200R ratios at diagnosis can be a useful and convenient biomarker to predict cross-sectional AAV activity calculated according to BVAS.
- Open Access
- 26 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2260
Remnant Cholesterol Levels at Diagnosis May Predict Acute Coronary Syndrome Occurrence During Follow-Up in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Objectives: Previous studies have revealed the predictive potential of remnant cholesterol (RC) for acute coronary syndrome (ACS) occurrence in the general population. However, whether this association applies to patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV), in which a lipid paradox exists, remains unclear. We investigated whether RC levels at diagnosis could predict ACS occurrence during follow-up in patients with AAV. Methods: This study included 139 patients with AAV. ACS was defined as ST-elevation myocardial infarction (STEMI), non-STEMI, or unstable angina occurring after AAV diagnosis. RC levels were calculated as (total cholesterol)–(low-density lipoprotein cholesterol)–(high-density lipoprotein cholesterol). Patients were categorised into three groups by RC tertiles: highest (≥26.2 mg/dL), middle (19.1−26.1 mg/dL), and lowest (≤19.0 mg/dL) tertile groups. Results: The median age of the 139 patients (male, 31.7%) was 58.0 years. During follow-up, six, two, and one patients were diagnosed with ACS in the highest, middle, and lowest tertile groups, respectively. Patients in the highest tertile group exhibited a significantly lower ACS-free survival rate than those in the lowest tertile (p = 0.030). In the multivariable Cox hazards model, male sex (hazard ratio [HR] 9.054, 95% confidence interval [CI] 1.786−45.910), Birmingham vasculitis activity score (HR 1.147, 95% CI 1.033−1.274), and the highest tertile of RC levels (HR 10.818, 95% CI 1.867–62.689) were significantly and independently associated with ACS occurrence during follow-up in patients with AAV. Conclusions: Our findings indicate that RC levels at diagnosis may predict ACS occurrence during follow-up in patients with AAV, regardless of the traditional cardiovascular risk factors.
- 26 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2260
Open AccessRemnant Cholesterol Levels at Diagnosis May Predict Acute Coronary Syndrome Occurrence During Follow-Up in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Objectives: Previous studies have revealed the predictive potential of remnant cholesterol (RC) for acute coronary syndrome (ACS) occurrence in the general population. However, whether this association applies to patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV), in which a lipid paradox exists, remains unclear. We investigated whether RC levels at diagnosis could predict ACS occurrence during follow-up in patients with AAV. Methods: This study included 139 patients with AAV. ACS was defined as ST-elevation myocardial infarction (STEMI), non-STEMI, or unstable angina occurring after AAV diagnosis. RC levels were calculated as (total cholesterol)–(low-density lipoprotein cholesterol)–(high-density lipoprotein cholesterol). Patients were categorised into three groups by RC tertiles: highest (≥26.2 mg/dL), middle (19.1−26.1 mg/dL), and lowest (≤19.0 mg/dL) tertile groups. Results: The median age of the 139 patients (male, 31.7%) was 58.0 years. During follow-up, six, two, and one patients were diagnosed with ACS in the highest, middle, and lowest tertile groups, respectively. Patients in the highest tertile group exhibited a significantly lower ACS-free survival rate than those in the lowest tertile (p = 0.030). In the multivariable Cox hazards model, male sex (hazard ratio [HR] 9.054, 95% confidence interval [CI] 1.786−45.910), Birmingham vasculitis activity score (HR 1.147, 95% CI 1.033−1.274), and the highest tertile of RC levels (HR 10.818, 95% CI 1.867–62.689) were significantly and independently associated with ACS occurrence during follow-up in patients with AAV. Conclusions: Our findings indicate that RC levels at diagnosis may predict ACS occurrence during follow-up in patients with AAV, regardless of the traditional cardiovascular risk factors.
- Open Access
Serum Glial Fibrillary Acidic Protein Can Predict Cross-Sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background and Objectives: Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein primarily produced by cells in the central nervous system (CNS) and other major organs such as the kidneys. This study investigated whether serum GFAP could be used to estimate cross-sectional vasculitis activity presented via the Birmingham vasculitis activity score (BVAS) in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Materials and Methods: This study included 74 patients with AAV. Clinical and laboratory data at diagnosis including BVAS and C-reactive protein (CRP) were reviewed. During follow-up, all-cause mortality and end-stage kidney disease (ESKD) were considered poor outcomes. Serum GFAP was measured from sera collected and stored at diagnosis. Results: The median age of the 74 patients was 63.5 years. Serum GFAP was inversely correlated with the cross-sectional BVAS (r = −0.373) and CRP (r = −0.320). It was also significantly correlated with general (r = −0.237) and renal (r = −0.335) manifestations among BVAS systemic items, and furthermore, among minor items of renal manifestation, correlating with sum scores for proteinuria (r = −0.409) and haematuria (r = −0.305). Additionally, compared with patients with serum GFAP > 194.9 pg/mL, those with serum GFAP ≤ 194.9 pg/mL showed a higher risk for progression to ESKD (relative risk 3.150) and a significantly lower cumulative ESKD-free survival rate. Conclusions: This study demonstrated the clinical potential of serum GFAP at diagnosis for predicting not only cross-sectional vasculitis activity through the anticipation of the extent of renal involvement but also future progression to ESKD in patients with AAV.
Open AccessSerum Glial Fibrillary Acidic Protein Can Predict Cross-Sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background and Objectives: Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein primarily produced by cells in the central nervous system (CNS) and other major organs such as the kidneys. This study investigated whether serum GFAP could be used to estimate cross-sectional vasculitis activity presented via the Birmingham vasculitis activity score (BVAS) in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Materials and Methods: This study included 74 patients with AAV. Clinical and laboratory data at diagnosis including BVAS and C-reactive protein (CRP) were reviewed. During follow-up, all-cause mortality and end-stage kidney disease (ESKD) were considered poor outcomes. Serum GFAP was measured from sera collected and stored at diagnosis. Results: The median age of the 74 patients was 63.5 years. Serum GFAP was inversely correlated with the cross-sectional BVAS (r = −0.373) and CRP (r = −0.320). It was also significantly correlated with general (r = −0.237) and renal (r = −0.335) manifestations among BVAS systemic items, and furthermore, among minor items of renal manifestation, correlating with sum scores for proteinuria (r = −0.409) and haematuria (r = −0.305). Additionally, compared with patients with serum GFAP > 194.9 pg/mL, those with serum GFAP ≤ 194.9 pg/mL showed a higher risk for progression to ESKD (relative risk 3.150) and a significantly lower cumulative ESKD-free survival rate. Conclusions: This study demonstrated the clinical potential of serum GFAP at diagnosis for predicting not only cross-sectional vasculitis activity through the anticipation of the extent of renal involvement but also future progression to ESKD in patients with AAV.
- Open Access
Circulating Malondialdehyde Is a Potential Biomarker for Predicting All-Cause Mortality during Follow-Up by Reflecting Comprehensive Inflammation at Diagnosis in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background and Objectives: To investigate whether circulating malondialdehyde (cMDA) at diagnosis could contribute to reflecting cross-sectional comprehensive inflammation or vasculitis activity and further predicting all-cause mortality during follow-up in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Materials and Methods: This study included 78 patients with AAV. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were collected as indices reflecting cross-sectional comprehensive inflammation, whereas the Birmingham vasculitis activity score (bVAS), and the five-factor score (FFS) were reviewed as AAV-specific indices. All-cause mortality was considered to be a poor outcome during follow-up. cMDA was measured from stored sera. Results: The median age of the 78 patients (32 men and 46 women) was 63.0 years. The median BVAS, FFS, ESR, and CRP were 5.0, 0, 24.5 mm/h, and 3.4 mg/L, respectively. Six patients died during the median follow-up duration based on all-cause mortality at 26.7 months. At diagnosis, cMDA was significantly correlated with cross-sectional ESR but not with BVAS or FFS. Compared to patients with cMDA < 221.7 ng/mL, those with cMDA ≥ 221.7 ng/mL at diagnosis exhibited an increased relative risk (RR 12.4) for all-cause mortality and further showed a decreased cumulative patient survival rate. Cox analyses revealed that cMDA ≥ 221.7 ng/mL (hazard ratio 24.076, p = 0.007) exhibited an independent association with all-cause mortality during follow-up in patients with AAV. Conclusions: cMDA at diagnosis may be a potential biomarker for predicting all-cause mortality during follow-up by reflecting comprehensive inflammation at diagnosis in patients with AAV.
Open AccessCirculating Malondialdehyde Is a Potential Biomarker for Predicting All-Cause Mortality during Follow-Up by Reflecting Comprehensive Inflammation at Diagnosis in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background and Objectives: To investigate whether circulating malondialdehyde (cMDA) at diagnosis could contribute to reflecting cross-sectional comprehensive inflammation or vasculitis activity and further predicting all-cause mortality during follow-up in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Materials and Methods: This study included 78 patients with AAV. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were collected as indices reflecting cross-sectional comprehensive inflammation, whereas the Birmingham vasculitis activity score (bVAS), and the five-factor score (FFS) were reviewed as AAV-specific indices. All-cause mortality was considered to be a poor outcome during follow-up. cMDA was measured from stored sera. Results: The median age of the 78 patients (32 men and 46 women) was 63.0 years. The median BVAS, FFS, ESR, and CRP were 5.0, 0, 24.5 mm/h, and 3.4 mg/L, respectively. Six patients died during the median follow-up duration based on all-cause mortality at 26.7 months. At diagnosis, cMDA was significantly correlated with cross-sectional ESR but not with BVAS or FFS. Compared to patients with cMDA < 221.7 ng/mL, those with cMDA ≥ 221.7 ng/mL at diagnosis exhibited an increased relative risk (RR 12.4) for all-cause mortality and further showed a decreased cumulative patient survival rate. Cox analyses revealed that cMDA ≥ 221.7 ng/mL (hazard ratio 24.076, p = 0.007) exhibited an independent association with all-cause mortality during follow-up in patients with AAV. Conclusions: cMDA at diagnosis may be a potential biomarker for predicting all-cause mortality during follow-up by reflecting comprehensive inflammation at diagnosis in patients with AAV.